Proliferative abilities of placenta-derived mesenchymal stem cells at different passages

doi:10.3969/j.issn.2095-4344.2014.10.018

Abstract

Abstract:

BACKGROUND: The mesenchymal stem cells which are from the placenta have better proliferative potential than the bone marrow mesenchymal stem cells. It is inconclusive, however, whether placenta-derived mesenchymal stem cells at different passages have the same proliferative ability.
OBJECTIVE: To analyze the proliferative ability of placenta-derived mesenchymal stem cells.
METHODS: Placenta-derived human mesenchymal stem cells were isolated with enzyme digestion, and flow cytometry was used to detect the cell surface markers. After osteogenic and adipogenic induction, cell proliferation detection was carried out using cell counting and BrdU analysis. Cell doubling time was calculated based on formula. The maximum cell passage was determined by long term cell culture until the cell died or differentiated.
RESULTS AND CONCLUSION: CD44, CD90 and CD105 were highly expressed in placenta-derived mesenchymal stem cells, while CD14, CD34 and CD45 were negatively expressed. After 21 days of adipogenic induction, oil red O staining showed red fat droplets; after 35 days of osteogenic induction, alizarin red staining showed calcium nodules. Cell counting started from passage 1 to 25, and cell number reached to 3.5×10¹¹ at passage 15. Cell proliferation at passage 5 was stronger with shorter doubling time than that at passages 10 and 15. When cells reached to passage 25, three specimens completely altered their cell morphology with cobblestone structure, and another two specimens lost adherent features. These findings indicate that
placenta-derived mesenchymal stem cells can be long-term subcultured upon to passage 25. Different proliferation capacities are found in different passages of placenta-derived mesenchymal stem cells. The proliferation ability of passage 5 placenta-derived mesenchymal stem cells is stronger than that of passage 10 and 15 cells. Placenta-derived mesenchymal stem cells at passages 0-5 are the important source for stem cell therapy and tissue engineering.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: stem cells, mesenchymal stem cells, placenta, cell proliferation

CLC Number:

R394.2

Bai Jin-ping, Li Xiu-ying, Li Xue, Yang Qi-wei, Liu Ying-nan, Wang Yi-min. Proliferative abilities of placenta-derived mesenchymal stem cells at different passages[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(10): 1591-1596.

Figures/Tables 4

References

[1]Maxson S, Lopez EA, Yoo D,et al. Role of Mesenchymal Stem Cells in Wound Repair. Stem Cells Trans Med. 2012; 1: 142-149.
[2]Patel DM, Shah J,Srivastava AS. Therapeutic Potential of Mesenchymal Stem Cells in Regenerative Medicine. Stem Cells International. 2013;(2013):15.
[3]Phinney DG, Prockop DJ.Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells.2007;25: 2896-2902.
[4]Pittenger MF, Mackay AM, Beck SC, et al.Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science. 1999;284(5411):143-147.
[5]Bilkovski R, Schulte DM, Oberhauser F,et al. Role of WNT-5a in the determination of human mesenchymal stem cells into preadipocytes.J Biol Chem.2010; 285: 6170-6178.
[6]Hematti P. Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev (Orlando).2008;22: 262-273.
[7]Kim DW, Staples M, Shinozuka K, et al. Wharton’s jelly derived Mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013; 14(6):11692-11712.
[8]Kuo CK,Tuan RS.Tissue engineering with mensenchymal stem cells. IEEE Eng Med Bio Mag.2003;22(5):51.
[9]Shin M,Yoshimoto H,Vacanti JP.In vivo bone tissue engineering using mesenchymal stem cells on a novel electrospun nano fibrous scaffold.Tissue Eng.2004; 10(1-2): 33.
[10]Marie PJ.Cell and gene therapy for bone repair. Osteoporos Int. 2011; 22: 2023-2026.
[11]Kon E, Filardo G, Roffi A, et al. Bone regeneration with mesenchymal stem cells. Clin Cases Miner Bone Metab. 2012; 9:24-27.
[12]Baksh D,Song L,Tuan RS.Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy.J Cell Mol Med.2004; 8(3):301-316.
[13]Matikainen T, Laine J.Placenta: An alternative source of stem cells. Toxicol Appl Pharmacol. Toxicol Appl Pharmacol. 2005; 207(2 suppl):544-549.
[14]Erices A, Conget P, Minguell JJ.Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol.2000; 109:235-242.
[15]Ilancheran S, Moodley Y, Manuelpillai U.Human fetal membranes: a source of stem cells for tissue regeneration and repair? Placenta.2009; 30: 2-10.
[16]Dai LJ, Moniri MR, Zeng ZR,et al. Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett.2011; 305: 8-20.
[17]Toubai T, Paczesny S, Shono Y, et al. Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation. Current stem cell research & therapy.2009; 4: 252-259.
[18]Parekkadan B, Milwid JM.Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010;12:87-117.
[19]D'Agostino B, Sullo N, Siniscalco D, et al.Mesenchymal stem cell therapy for the treatment of chronic obstructive pulmonary disease. Expert Opin Biol Ther. 2010; 10:681.
[20]Liu YH, Vaghjiani V, Tee JY, et al.Amniotic epithelial cells from the human placenta potently suppress a mouse model of multiple sclerosis.PLoS One. 2012;7(4):1-8.
[21]Hayashi N,Takahashi K,Abe Y, et al. Placental/umbilical cord blood- derived mesenchymal stem cell-like stromal cells support hematopoietic recovery of X-irradiated human CD34~+ cells. Life Sciences. 2009; 84(17-18):598-605.
[22]Pittenger MF, Mackay AM, Beck SC, et al. Multilineage po tential of adu lt hum an mesenchyma l stem cell. Science. 1999;284(2): 143-147.
[23]Bianco P, Gehron RP. Marrow stromal stem cells. J Clin Invest. 2000; 105:1663-1668.
[24]Vaanaenaen HK. Mesenchymal stem cells. Ann Med.2005; 37: 469-479.
[25]Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther.2007;9: 204.
[26]He Q, Wan C, Li G. Concise review: multipotent mesenchymal stromal cells in blood. Stem Cells.2007;25: 69-77.
[27]Van Den Berk LC, Figdor CG, et al. Mesenchymal stromal cells:tissue engineers and immune response modulators. Arch Immunol Ther Exp(Warsz).2008;56: 325-329.
[28]Zhu SF, Zhong ZN, Fu XF, et al.Comparison of cell proliferation, apoptosis, cellular morphology and ultrastructure between human umbilical cord and placenta-derived mesenchymal stem cells. Neuroscience letters.2013; 541: 77-82.
[29]Kadam S, Muthyala S, Nair P, et al.Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes.Rev Diabet Stud. 2010;7(2):168-182.
[30]Parolini O, Alviano F, Bergwerf I,et al.Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. Stem Cells and Development.2010; 19(2): 143-154.
[31]Tuan RS, Boland G, Tuli R. Adult mesenchymal stem cells and cell-based tissue engineering. Arthritis Res Ther.2003; 5:32-45.
[32]Fukuchi Y, Nakajima H, Sugiyama D, et al. Human placenta-derived cells have mesenchymal stem/progenitor cell potential.Stem Cells.2004;22: 649-658.
[33]Yen BL, Huang HI, Chien CC, et al.Isolation of multipotent cells from human term placenta. Stem Cells.2005;23(1):3-9.
[34]Miao Z, Jin J, Chen L, et al. Isolation of mesenchymal stem cells from human placenta: Comparison with human bone marrow mesenchymal stem cells. Cell Biol Int. 2006;30(9): 681-687.
[35]Vikram Sabapathy, Saranya Ravi, Vivi Srivastava,et al . Long-term cultured human term placenta-derived mesenchymal stem cells of maternal origin displays plasticity.Stem Cells International.2012;(2012):11.
[36]Nazarov I, Lee JW, Soupene E, et al. Multipotent Stromal Stem Cells from Human Placenta Demonstrate High Therapeutic Potential. Stem Cells Translational Medicine. 2012;1(5):359-372.
[37]Groza I, Pall E, Groza D,et al. Evaluation of multipotent mesenchymal stem cells from human placenta. Lucr?ri Tiin?ifice Medicin? Veterinar Vol. 2010; Xliii (2):9-14.
[38]Parolini O, Alviano F, Bagnara G, et al.Isolation and characterization of cells from human term placenta: Outcome of the First International workshop on placenta derived stem cells. Stem Cells. 2008;26:300-311.
[39]Prockop DJ, Sekiya I, Colter DC. Isolation and characterization of rapidly self-renewing stem cells from cultures of human marrow stromal cells. Cytotherapy.2001;3 (5):393-396.
[40]Majumdar MK,Keane-Moore M,Buyaner D,et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci.2003;10: 228-241.
[41]Gekas C, Rhodes KE, Mikkola HK,et al. Isolation and analysis of hematopoietic stem cells from the placenta. J Vis Exp. 2008; 6:742.
[42]李丽春,何治,李剑平.胎盘间充质干细胞的体外诱导分化[J].中国组织工程研究, 2013,17(6):1116-1119.
[43]Chamberlain G, Fox J, Ashton B, et al. Concise review: mesenchymal stem cells: their phenotype, diferentiation capacity, immunological features, and potential for homing. Stem Cells. 2007; 25(11): 2739-2749.
[44]Oswald J,Boxberger S,Jorgensen B,et al.Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells.2004;22(3):377-384.
[45]Chien CC, Yen BL, Lee FK, et al.In vitro differentiation of human placenta-derived multipotent cells into hepatocyte-like cells. Stem Cells. 2006;24(7):1759-1760.
[46]Pravin D. Potdar,Preeti Prasannan. Differentiation of Human Dermal Mesenchymal Stem Cells into Cardiomyocytes by Treatment with 5-Azacytidine: Concept for Regenerative Therapy in Myocardial Infarction. ISRN Stem Cells, 2013; (2013):9.
[47]万振洲,冯亚松,彭海林,等.体外诱导胎盘间充质干细胞向表皮细胞的分化[J].中国组织工程研究与临床康复,2011, 15(49):9223- 9226.
[48]Parolini O,Alviano F,Bagnara GP,et al.Isolation and char-acterization of cells from human term placenta:outcome of thefirst international workshop on placenta derived stem cells. Stem Cells. 2008;26(2):300-311.
[49]张红艳,杨乃龙.胎盘来源间充质干细胞的生物学特征[J].中国组织工程究,2010,14(40):7535-7538.
[50]Pipino C, Shangaris P, Resca E,et al.Placenta as a reservoir of stem cells: an underutilized resource? Br Med Bull. 2013; 105:43-68.